Anatara Lifesciences Ltd (ANR) - Total Assets
Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) holds total assets worth AU$1.15 Million AUD (≈ $812.56K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anatara Lifesciences Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Anatara Lifesciences Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Anatara Lifesciences Ltd for the company's overall valuation and market capitalisation.
Anatara Lifesciences Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Anatara Lifesciences Ltd's total assets of AU$1.15 Million consist of 100.0% current assets and 0.0% non-current assets. Review total liabilities of Anatara Lifesciences Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 8.8% |
| Accounts Receivable | AU$1.03 Million | 89.5% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Anatara Lifesciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Anatara Lifesciences Ltd stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anatara Lifesciences Ltd's current assets represent 100.0% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2025, down from 75.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 89.5% of total assets.
Anatara Lifesciences Ltd Competitors by Total Assets
Key competitors of Anatara Lifesciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
Anatara Lifesciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 5.49 | 7.19 |
| Quick Ratio | 1.89 | 7.70 | 7.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$541.12K | AU$1.37 Million | AU$2.87 Million |
Anatara Lifesciences Ltd - Advanced Valuation Insights
This section examines the relationship between Anatara Lifesciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.98 |
| Latest Market Cap to Assets Ratio | 1.37 |
| Asset Growth Rate (YoY) | -31.3% |
| Total Assets | AU$1.15 Million |
| Market Capitalization | $1.57 Million USD |
Valuation Analysis
Above Book Valuation: The market values Anatara Lifesciences Ltd's assets above their book value (1.37x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Anatara Lifesciences Ltd's assets decreased by 31.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anatara Lifesciences Ltd (2011–2025)
The table below shows the annual total assets of Anatara Lifesciences Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.15 Million ≈ $812.56K |
-31.29% |
| 2024-06-30 | AU$1.67 Million ≈ $1.18 Million |
+17.76% |
| 2023-06-30 | AU$1.42 Million ≈ $1.00 Million |
-19.70% |
| 2022-06-30 | AU$1.77 Million ≈ $1.25 Million |
-59.15% |
| 2021-06-30 | AU$4.33 Million ≈ $3.06 Million |
+29.40% |
| 2020-06-30 | AU$3.34 Million ≈ $2.37 Million |
-47.61% |
| 2019-06-30 | AU$6.38 Million ≈ $4.52 Million |
-34.96% |
| 2018-06-30 | AU$9.81 Million ≈ $6.94 Million |
-20.33% |
| 2017-06-30 | AU$12.32 Million ≈ $8.71 Million |
-11.52% |
| 2016-06-30 | AU$13.92 Million ≈ $9.85 Million |
+147.34% |
| 2015-06-30 | AU$5.63 Million ≈ $3.98 Million |
-24.50% |
| 2014-06-30 | AU$7.45 Million ≈ $5.27 Million |
+10209.22% |
| 2013-06-30 | AU$72.30K ≈ $51.16K |
+44.60% |
| 2012-06-30 | AU$50.00K ≈ $35.38K |
+1150.00% |
| 2011-06-30 | AU$4.00K ≈ $2.83K |
-- |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more